Clinical Trial Update: Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma

View source ↗

Summary

Marketing approval for Ultratrace iobenguane I-131 has been granted for malignant relapsed/refractory pheochromocytoma and paraganglioma, per an expanded access…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paraganglioma
• Pheochromocytoma

Drugs mentioned

• Ultratrace Iobenguane I-131 (iobenguane I-131)

Snippet

Sponsor: Molecular Insight Pharmaceuticals, Inc. | Conditions: Pheochromocytoma, Paraganglioma | Status: APPROVED_FOR_MARKETING